RhumbLine Advisers
EVLO

RhumbLine Advisers’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

RhumbLine Advisers’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,441
Closed -$98K – 3304
2022
Q1 		$98K Buy
1,441
+244
+20% +$20.3K ﹤0.01% 2889
2021
Q4 		$145K Buy
1,197
+15
+1% +$2.53K ﹤0.01% 2892
2021
Q3 		$166K Buy
1,182
+51
+5% +$10.1K ﹤0.01% 2938
2021
Q2 		$311K Buy
1,131
+151
+15% +$38.1K ﹤0.01% 2770
2021
Q1 		$210K Buy
980
+11
+1% +$3.04K ﹤0.01% 2820
2020
Q4 		$234K Buy
969
+109
+13% +$13.5K ﹤0.01% 2771
2020
Q3 		$91K Sell
860
-29
-3% -$2.64K ﹤0.01% 2883
2020
Q2 		$87K Sell
889
-127
-13% -$11.1K ﹤0.01% 2983
2020
Q1 		$76K Hold
1,016
– – ﹤0.01% 2824
2019
Q4 		$83K Buy
1,016
+14
+1% +$1.57K ﹤0.01% 2889
2019
Q3 		$122K Buy
1,002
+71
+8% +$9.76K ﹤0.01% 2855
2019
Q2 		$167K Buy
931
+171
+23% +$27.6K ﹤0.01% 2835
2019
Q1 		$122K Buy
+760
New +$150K ﹤0.01% 2835

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RhumbLine Advisers's EVLO Position: Q2 2022 in Review

RhumbLine Advisers sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2022, closing a stake of 1,441 shares — an estimated $98K sold.

RhumbLine Advisers first reported a position in EVLO in Q1 2019 and held it in 13 quarters. The position peaked at $311K in Q2 2021. 46 funds tracked by Wall St. Rank hold EVLO as of Q2 2022.

  • RhumbLine Advisers reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 1,441 Evelo Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $98K.
  • RhumbLine Advisers first reported a position in Evelo Biosciences, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
  • RhumbLine Advisers's Evelo Biosciences, Inc. Common Stock position peaked at $311K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.